Taipei Exchange - Delayed Quote TWD

GlycoNex Incorporation (4168.TWO)

24.00

0.00

(0.00%)

At close: 1:30:31 PM GMT+8

GlycoNex reports positive results for denosumab biosimilar Phase I trial

The results showed SPD8's pharmacokinetic profile, safety and pharmacodynamics were comparable to those of the reference biologic.

Clinical Trials Arena 4 months ago

4168.TWO
0.00%

Performance Overview

Return	4168.TWO	TSEC CAPITALIZATION WEIGHTED ST
YTD	-5.14%	-0.71%
1-Year	-13.36%	+31.22%
3-Year	-19.48%	+25.11%